Trial
NCT01099761
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
ACE-031 0.5 mg/kg q4wk
Why stopped
Based on preliminary safety data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-13